跳到正文
原文
STAT Pharma 医药频道· Ed Silverman·· 27 天前AI 评分47

分析显示:欧洲监管下大多数癌症新药缺乏高临床获益

STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

AI 导读

对欧洲监管机构近4年批准的97项适应症分析显示,仅31%具备高临床获益,其中9项获最高评级。63种癌症新药中仅19种被认定至少有一项高获益适应症。2022年1月至2026年7月批准的30项高获益适应症中,超过半数来自5家药企,其中4家位于中日。

正文

By Ed Silverman

Oct. 23, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit and those that do were generated by a small number of drugmakers, mostly based in Asia, according to a new analysis.

Just 31% of 97 approved indications for 63 different cancer treatments offered a high clinical benefit and only nine of those medications received the top grade based on measurement tools used by the European Society for Medical Oncology. And of the 63 cancer drugs, just 19 were deemed to have at least one high-benefit indication.

Meanwhile, five drugmakers accounted for more than half of all 30 high-benefit indications for medicines approved by European regulators from January 2022 through July 2026. And four of those five companies are based in either China or Japan, which the researchers suggested is a “fundamental shift in the innovation ecosystem” over the past decade.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com